

BUY AB Capital

Your success is our success

Strong show amid noise around lower-ticket unsecured retail loansBFSI - NBFCs ▶ Result Update ▶ **November 5, 2023****TARGET PRICE (Rs) : 225**

ABCAP registered a sturdy performance in Q2FY24, with the lending business delivering robust loan-book/profitability growth, asset quality seeing slight improvement and the non-lending business witnessing a steady performance. The company sees its smaller ticket unsecured retail-loan portfolio holding up per expectations, and maintains its continuous monitoring and calibration of growth, interest rate and payouts to partners, in sync with emerging asset-quality trends. With Company's abiding investment journey on the tech front, building an omni-channel distribution network and realizing its synergies with the AB Group ecosystem, the management preserves an optimistic outlook. Given the Q2FY24 performance and positive growth outlook, we keep our FY24-26 estimates unchanged and reiterate our BUY rating on the stock, with an unchanged Sep-24E TP of Rs 225/share.

AB Capital: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	17,060	47,958	28,405	36,099	43,721
Adjusted PAT	15,100	20,567	28,405	36,099	43,721
Networth	154,921	203,108	260,769	296,868	340,589
RoE (%)	10.3	11.5	12.2	12.9	13.7
Lending Book growth (%)	10.3	41.1	25.4	20.3	18.3
Adj. EPS (Rs)	6.2	8.5	11.1	13.9	16.9
Adj. EPS growth (%)	33.8	36.1	31.0	24.9	21.1
Adj. BV (Rs)	64.1	84.1	100.5	114.5	131.3
Adj. BVPS growth (%)	12.7	31.1	19.6	13.8	14.7
ABFL RoA (%)	2.2	2.3	2.5	2.6	2.6
ABFL RoE (%)	12.1	14.7	16.9	17.0	17.3
P/E (x)	27.7	20.3	15.5	12.4	10.3
P/ABV (x)	2.7	2.1	1.7	1.5	1.3

Source: Company, Emkay Research

Delivers another strong quarter of growth and profitability

The NBFC business saw a robust 44% YoY AUM growth and 32% YoY disbursement growth. While NIM marginally dipped on sequential basis to 6.87%, RoA stood at 2.51% for Q2FY24. Given the rising unsecured loans, write-off at Rs3.7bn for Q2 stayed high, but credit cost at 1.59% was just a minor increase QoQ. The HFC business saw steady AUM growth of 24% YoY and 6% QoQ, whereas NIM came in at 4.88%, translating into an improved RoA of 2.03%. The Life Insurance business saw 13% YoY growth in Individual APE during H1FY24, whereas VNB margin logged an improvement to 14.2%. The Health Insurance business saw ~23% growth in gross premiums, and H1 combined ratio at 119% (up 7ppts). The AMC business saw 5% QoQ growth in AUM to Rs3,109bn; however, PAT declined 4% QoQ to Rs1.8bn. ABCAP reported an overall healthy performance, with consolidated revenue growing 22% YoY/8% QoQ to Rs88.3bn, while PAT grew 44% YoY/9% QoQ to Rs7.05bn during Q2FY24 (Exhibit 1).

Continuous investments in tech and distribution

ABCAP continues to invest in technology and building an omni channel distribution network. Further synergies with the ABG ecosystem are expected to fire the loan-book growth over the next few years. While the management has calibrated the growth in the small-ticket unsecured loan segment, various initiatives including the UDYOG Plus and the B2C platform are expected to fuel the growth momentum for the lending business, leading to the company achieving its guidance of doubling the loan book every 3 years. Given its widespread distribution network and the Aditya Birla brand, the Life and Health Insurance businesses are expected to clock better-than-industry growth going forward.

We reiterate BUY, with unchanged Sep-24E target price of Rs225/share


Against the backdrop of an in-line Q2FY24 performance, we have kept our FY24-26 estimates unchanged and reiterate our BUY rating on the stock, with an unchanged Sep-24E SOTP-based TP of Rs225/share (FY25E P/B of 2x for ABFL and 1.8x for ABHFL). With the lending businesses firing up, ABCAP is well positioned; however, the broader sector concern around low-ticket unsecured retail loans is likely to weigh on the share price in the near term (Exhibit 2).

Target Price – 12M	Sep-24
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	30.0
CMP (03-Nov-23) (Rs)	173.1

Stock Data	Ticker
52-week High (Rs)	199
52-week Low (Rs)	116
Shares outstanding (mn)	2,599.4
Market-cap (Rs bn)	450
Market-cap (USD mn)	5,403
Net-debt, FY24E (Rs mn)	0
ADTV-3M (mn shares)	4
ADTV-3M (Rs mn)	690.0
ADTV-3M (USD mn)	8.3
Free float (%)	-
Nifty-50	19,231
INR/USD	83.3
Shareholding, Sep-23	
Promoters (%)	69.0
FPIs/MFs (%)	10.5/9.1

Price Performance

(%)	1M	3M	12M
Absolute	(4.2)	(10.4)	44.6
Rel. to Nifty	(2.7)	(9.7)	35.7

1-Year share price trend (Rs)**Avinash Singh**

avinash.singh@emkayglobal.com
+91 22 6612 1327

Mahek Shah

mahek.shah@emkayglobal.com
+91 22 6612 1218

Exhibit 1: Quarterly Financial Performance

	Q2FY24	Q2FY23	YoY	Q1FY24	QoQ
Aditya Birla Capital (Consolidated)					
Consolidated Revenue (Rs mn)	88,310	72,100	22%	81,440	8%
Consolidated PAT (Rs mn)	7,050	4,880	44%	6,488	9%
Lending Book (Rs mn)	10,89,610	7,74,300	41%	10,04,000	9%
Gross Premium (Rs mn)	45,110	43,930	3%	38,770	16%
Total AUM (Rs bn)	4,044	3,600	12%	3,900	4%
Aditya Birla Finance					
Lending Book (Rs mn)	9,35,220	6,49,750	44%	8,58,910	9%
Net Interest Margin (%)	6.87	6.58	0.3ppts	6.98	-0.1ppts
Net Interest Income (Rs mn)	15,200	9,980	52%	14,330	6%
Credit Provisioning (%)	1.59	1.32	0.3ppts	1.51	0.1ppts
Profit After Tax (Rs mn)	5,480	3,580	53%	5,160	6%
Return On Asset (%)	2.51	2.40	0.1ppts	2.54	0.0ppts
Return On Equity (%)	18.0	14.7	3.3ppts	17.9	0.1ppts
Aditya Housing Finance					
Lending Book (Rs mn)	1,54,390	1,24,550	24%	1,45,090	6%
Net Interest Margin (%)	4.88	5.13	-0.3ppts	5.11	-0.2ppts
Credit Provisioning (%)	0.03	0.67	-0.6ppts	0.15	-0.1ppts
Profit After Tax (Rs mn)	750	590	27%	650	15%
Return On Asset (%)	2.03	1.94	0.1ppts	1.90	0.1ppts
Return On Equity (%)	14.50	13.87	0.6ppts	13.23	1.3ppts
Aditya Birla Sun Life AMC					
MFQAAUM (Rs bn)	3,109	2,826	10%	2,969	5%
Revenue (Rs mn)	3,350	3,880	-14%	3,890	-14%
Cost to Income Ratio	46%	36%	29%	38%	20%
PAT (Rs mn)	1,780	1,920	-7%	1,850	-4%
Aditya Birla Sun Life Insurance					
	H1FY24	H1FY23	YoY		
Individual APE (Rs mn)	11,890	10,510	13%		
New Business Premium (Rs mn)	33,070	34,220	-3%		
Net VNB (%)	14.2	12.30	1.9ppts		
Opex Ratio (Incl. Commission; %)	20.2	18.8	1.4ppts		
PAT (Rs mn)	350	580	-40%		
Aditya Birla Health Insurance					
Retail Premium (Rs mn)	4,440	4,210	5%	3,650	22%
Group Premium (Rs mn)	3,400	2,190	55%	4,060	-16%
Gross Premium (Rs mn)	7,940	6,400	24%	7,720	3%
Combined Ratio – H1 (%)	119	112	7.0ppts		
Profit Before Tax (Rs mn)	-780	-790	-1%	-620	NM

Source: Company, Emkay Research

Exhibit 2: We arrive at SOTP-based Sep-24E TP of Rs225/share

Entity	Metrics	Mar-25	Multiple (x)	Valuation (Rs mn)	Ownership	Value	Rs per share
NBFC	Net worth (Rs mn)	1,86,410	2.0	3,72,821	100%	3,72,821	144
HFC	Net worth (Rs mn)	31,639	1.8	56,950	100%	56,950	22
AMC	MCAP (Rs mn)	1,28,380	1.0	1,28,380	50%	64,203	25
Life Insurance	EV (Rs mn)	1,24,234	1.5	1,86,351	51%	95,039	37
Health Insurance	Deal value (Rs mn)	86,450	1.0	86,450	46%	39,681	15
AB Money	MCAP (Rs mn)	6,160	1.0	6,160	74%	4,558	2
Others		10000	1.0	10,000	50%	5,000	2
Total						6,38,252	246
Holding company discount			25%			52,120	20
Fair value						5,86,132	225
No. of shares (mn)						2,594	
Fair value per share	(Rs/share)					225	

Source: Company, Emkay Research; Note: Holding company discount applied on non-wholly-owned subsidiaries only

Earnings Conference Call Highlights

Consolidated Business:

- The company is following an omnichannel architecture for distribution, giving customers complete flexibility to choose the channel of interaction. 'Digital first' remains at the core of the company's strategy for product innovation, direct acquisition and seamless transaction experience.

Lending Business:


- The UDYOG Plus platform saw more than 164,000 registrations as of Sep-23. The platform offers small-ticket business loans along with various value-added services. The company has integrated the UDYOG Plus platform with several government and private e-commerce websites, to provide various credit facilities to sellers on these platforms. Aditya Birla Finance (ABFL) has also started integrating UDYOG Plus with the Aditya Birla Group (ABG) ecosystem to provide channel financing to dealers. UDYOG plus has reached a monthly run-rate of Rs500mn disbursement, with ABG ecosystem contributing two-thirds of this business.
- ABFL is developing an omnichannel B2C platform with various touchpoints, to acquire customers and provide holistic solutions to existing customers. The management said the company is progressing well on this project and the mobile app is expected to be ready by the next quarter.
- All products contributed to growth, with the business-loan segment contributing to 41% of the disbursement mix, followed by the personal & consumer (P&C) segment at 32%.
- Aditya Birla Housing Finance (ABHFL) remains focused on origination of quality customers, with 96% of the disbursements towards 700-plus CIBIL customers and NTCs.
- Contribution of NHB in ABHFL's borrowing mix inched up, from 16% to 21%, as of Sep-23.
- Finverse—a digital lending platform offering unified interface for all stakeholders including customers, partners, employees and vendors with 95-plus API integrations—has been deployed across all branches.
- The unsecured P&C loan with ticket size less than Rs50,000 and tenure less than 30 days contributes to only 1% of the portfolio, which remains stable.
- Management has started monitoring the Unsecured P&C portfolio closely, and tightened the underwriting standards and scorecards. Initially, all indicators are looking adequate and the management does not have any concerns regarding the small-ticket unsecured P&C portfolio.
- Of the customers on-boarded 9 months ago, 12% have a leverage that is 1.5 times the leverage before being on-boarded. Hence, the management is closely tracking the leverage of such customers.
- The management has started calibrating the growth in the P&C segment by 21% QoQ growth in Q4FY23, 15% QoQ growth during Q1FY24, and 9% QoQ growth during Q2FY24.
- The management said that the underwriting and credit standards across channels are identical and, hence, even though the customer is on-boarded through the digital channel, the underwriting standards remain the same.
- Margin for NBFC business saw a slight dip sequentially, on account of slightly higher cost of funds.
- The management gave guidance that RoA should improve to 3% in the next three years, driven by changes in product mix and improved margins; it targets doubling the loan book every three years.
- In the Developer Finance segment, exposure remains primarily towards the Mumbai, Pune and Bengaluru regions.
- While the management will not miss out on any opportunity in the corporate loan segment, growth will be primarily driven by the retail and SME segments.
- Growth in the loan book was driven by growth in the average ticket size.

Insurance business

- The Individual life insurance business saw growth of 13% in H1FY24, higher than the industry growth of ~8%, which was supported by ~19% growth in number of policies.
- Growth in the life insurance business was driven by ~22% growth in the Proprietary channels, whereas the largest banca channel saw degrowth on account of a strategic shift to contribute more to the subsidiary life insurance partner.
- Aditya Birla Sun Life Insurance (ABSLI) on-boarded IDFC Bank as its banca partner and Bank of Maharashtra will be on-boarded during Nov-23.
- Margin expansion in H1FY24 was driven by share of traditional products in the mix and an uptake of protection products and improved productivity.
- The management expects VNB margin to reach 23% by the end of the year. It continues to aim for above-industry growth, backed by both productivity and capacity.
- While the Health Insurance business witnessed slow growth of 23% during H1FY24, the management expects the growth traction to continue post the changes in the channel strategy.
- Combined Ratio for Aditya Birla Health Insurance (ABHI) was higher than previous year's, largely led by seasonality in growth. The management said that the company will continue normalizing the combined ratio in coming quarters.
- While the retail Health loss ratio is trending downward, the corporate loss ratio remains in the quoted range. Management continues to capture the opportunity in the Health Insurance space while remaining profitable.


Story in Charts

Exhibit 3: ABFL posts a robust Loan Book growth of 44% YoY




Source: Company, Emkay Research

Exhibit 4: ABHFL reports a steady loan-book growth of 24% YoY




Source: Company, Emkay Research

Exhibit 5: ABHI's GDPI grows 24% YoY to Rs7.94bn




Source: Company, Emkay Research

Exhibit 6: ABSLI's APE grows to Rs11.9bn during H1FY24




Source: Company, Emkay Research

Exhibit 7: ABSLAMC reports MFQAAUM growth of 5% QoQ




Source: Company, Emkay Research

Exhibit 8: ABCAP's consolidated PAT grows 44% YoY




Source: Company, Emkay Research

Exhibit 9: We expect ABFL's loan book to grow 25% during FY24E




Source: Company, Emkay Research

Exhibit 10: We expect ABHFL's Loan Book to grow by 27% in FY24E




Source: Company, Emkay Research

Exhibit 11: ABSLI's growth APE is expected to moderate to 1.8% during FY24E




Source: Company, Emkay Research

Exhibit 12: ABHI's GDPI is expected to grow 34% during FY24E




Source: Company, Emkay Research

Exhibit 13: We expect ABCAP to deliver healthy RoE of 12% by FY24E



Source: Company, Emkay Research

Exhibit 14: ABCAP's Consolidated EPS is expected to grow to Rs11.14/share during FY24E



Source: Company, Emkay Research

Exhibit 15: ABCAP (Consolidated) – Financial Summary

(Rs mn)	FY21	FY22	FY23	FY24E	FY25E	FY26E
Profit before tax						
NBFC	10,314	14,871	20,902	30,555	38,976	46,923
Housing Finance	1,764	2,533	3,085	3,916	4,995	6,192
Asset Management	6,959	8,652	7,939	8,260	9,042	9,920
Life Insurance	1,179	1,409	1,538	1,908	2,111	2,585
Health Insurance	-1,977	-3,114	-2,188	-1,919	-115	2,015
General Insurance Broking	707	860	970			
AB Money	224	357	467	350	350	350
Others and Elimination	-3,714	-2,700	23,519	-4,322	-4,712	-5,150
Total PBT	15,457	22,867	56,352	38,749	50,647	62,835
Tax expense	4,400	6,267	8,112	10,462	13,675	16,965
Profit after tax	11,057	16,601	48,241	28,287	36,972	45,869
Minority interest	-209	-459	283	-117	874	2,148
Group Net income	11,265	17,060	47,958	28,405	36,099	43,721
Preference dividend	0	0	0	0	0	0
One-off adjustments		-1,960	-27,391			
Adjusted Group Net Income	11,265	15,100	20,567	28,405	36,099	43,721
Total Assets						
NBFC	5,07,552	5,69,692	8,41,228	10,53,513	12,65,491	14,89,085
Housing Finance	1,23,758	1,25,907	1,40,721	1,78,102	2,16,455	2,64,054
Life Insurance	5,32,595	6,16,673	7,11,886	8,32,834	9,77,157	11,49,351
Asset Management	19,846	24,343	27,766	33,320	39,984	47,980
Health Insurance	13,813	18,181	27,681	32,681	32,682	34,697
Other Businesses & Elimination	50,379	56,599	58,257	67,278	76,463	86,792
Total	12,47,942	14,11,395	18,07,541	21,97,728	26,08,231	30,71,960
Per share (Rs)						
Adjusted EPS (Basic)	4.67	6.25	8.51	11.14	13.92	16.86
Reported EPS (Basic)	4.67	7.06	19.83	11.14	13.92	16.86
BVPS (Rs)	56.90	64.11	84.06	100.54	114.46	131.31

Source: Company, Emkay Research

Exhibit 16: Aditya Birla Finance – Financial Summary

(Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Income Statement					
Interest income	55,313	78,060	1,11,678	1,36,091	1,61,517
Interest expense	27,091	38,572	53,966	64,740	76,072
Net interest income	30,758	43,797	63,590	78,513	93,945
Other income	120	308	164	189	218
Total income	30,878	44,105	63,754	78,702	94,163
Employee expense	5,207	7,228	9,035	10,843	13,011
Depreciation	684	861	1,115	1,331	1,539
Other expense	3,581	6,079	7,598	9,118	10,942
Opex	9,472	14,168	17,749	21,291	25,492
Profit before provisions	21,406	29,937	46,005	57,411	68,671
Provisions	6,535	9,035	15,449	18,435	21,748
Profit before tax	14,871	20,902	30,555	38,976	46,923
Tax expense	3,788	5,364	7,639	9,744	11,731
Reported profit attributable to shareholders	11,318	15,610	22,916	29,232	35,192
Balance Sheet					
Shareholders' Equity	98,604	1,14,262	1,57,179	1,86,410	2,21,603
Borrowings	4,59,857	7,07,707	8,66,285	10,49,898	12,35,516
Other liabilities	11,230	19,259	30,049	29,182	31,967
Total equity & liabilities	5,69,692	8,41,228	10,53,513	12,65,491	14,89,085
Assets					
Cash & cash equivalents	6,925	3,876	4,855	5,832	6,864
Investments	16,940	37,027	46,375	55,711	65,561
Loans & advances	5,36,075	7,88,495	9,87,565	11,86,384	13,96,133
Fixed assets	2,217	3,101	3,786	4,429	5,073
Other assets	7,535	8,729	10,932	13,133	15,455
Total Assets	5,69,692	8,41,228	10,53,513	12,65,491	14,89,085
Gross loans	5,46,821	8,04,520	10,06,844	12,09,320	14,23,551
GNPA	19,560	25,070	29,558	34,531	40,993
NNPA	11,831	13,488	15,962	18,646	22,136
Key ratios (%)					
Asset yield	11.4	12.4	13.2	13.2	13.2
Cost of funds	6.2	6.6	6.9	6.8	6.7
Spread	5.2	5.8	6.4	6.4	6.5
Net interest margin	6.1	6.6	7.2	7.2	7.3
Opex % of AAUM)	1.9	2.1	2.0	2.0	2.0
C/I ratio	30.7	32.1	27.8	27.1	27.1
Credit cost	1.29	1.4	1.7	1.7	1.7
RoA	2.18	2.26	2.46	2.57	2.60
RoE	12.1	14.7	16.9	17.0	17.3
Tier I	18.1	13.9	16.7	16.3	16.3
CRAR	21.8	16.4	18.9	18.1	17.9
D/E (x)	4.7	6.2	5.5	5.6	5.6
Leverage (x)	5.8	7.4	6.7	6.8	6.7
Per share (Rs)					
Reported EPS - Basic	16.74	23.47	34.46	43.95	52.91
Reported EPS - Diluted	16.74	23.47	34.46	43.95	52.91
DPS	0.00	0.00	0.00	0.00	0.00
BVPS	148.9	172.6	237.4	281.5	334.7
RoA Tree (%)					
Interest income	10.3	11.1	11.8	5.9	5.9
Interest expense	5.0	5.5	5.7	5.6	5.5
Net interest income	5.7	6.2	6.7	6.8	6.8
Other income	0.0	0.0	0.0	0.0	0.0
Total income	5.7	6.3	6.7	6.8	6.8
Employee expense	1.0	1.0	1.0	0.9	0.9
Depreciation	0.1	0.1	0.1	0.1	0.1
Other expense	0.7	0.9	0.8	0.8	0.8
Opex	1.8	2.0	1.9	1.8	1.9
Profit before provisions	4.0	4.2	4.9	5.0	5.0
Provisions	1.2	1.3	1.6	1.6	1.6
Profit before tax	2.8	3.0	3.2	3.4	3.4
Tax expense	0.7	0.8	0.8	0.8	0.9
Recurring profit after tax	2.06	2.20	2.42	2.52	2.56

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/15/2023 11:50 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 17: Aditya Birla Housing Finance – Financial Summary

(Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Income Statement					
Interest income	11,857	13,640	16,956	21,006	25,607
Interest expense	6,949	7,484	9,305	11,526	14,160
Net interest income	5,202	6,569	8,147	10,072	12,155
Other income	11	22	30	30	30
Total income	5,213	6,591	8,177	10,102	12,185
Employee expense	1,317	1,790	2,148	2,535	2,991
Other expense	516	833	916	1,008	1,109
Opex	1,934	2,782	3,262	3,776	4,372
Profit before provisions	3,280	3,809	4,914	6,326	7,813
Provisions	747	724	998	1,331	1,621
Profit before tax	2,533	3,085	3,916	4,995	6,192
Tax expense	560	676	858	1,094	1,357
Recurring profit after tax	1,973	2,409	3,058	3,901	4,835
Other Comprehensive Income	45	54	0	0	0
Profit attributable to equity shareholders	2,018	2,464	3,058	3,901	4,835
Balance Sheet					
Shareholders' Equity	17,210	19,680	27,738	31,639	36,474
Borrowings	1,07,152	1,19,372	1,49,248	1,82,974	2,25,178
Other liabilities	1,545	1,669	1,115	1,842	2,402
Total equity & liabilities	1,25,907	1,40,721	1,78,102	2,16,455	2,64,054
Assets					
Cash & cash equivalents	5,570	2,047	2,592	3,151	3,844
Loans & advances	1,18,955	1,35,570	1,71,631	2,08,631	2,54,559
Fixed assets	337	721	861	1,005	1,175
Other assets	1,045	2,384	3,018	3,668	4,476
Total Assets	1,25,907	1,40,721	1,78,102	2,16,455	2,64,054
Key ratios (%)					
Loan yield	10.3	11.0	11.4	11.4	11.4
Cost of funds	6.5	6.6	6.9	6.9	6.9
Spread	3.8	4.4	4.4	4.4	4.4
Net interest margin	4.4	5.2	5.3	5.3	5.2
C/I ratio	37.1	42.2	39.9	37.4	35.9
Credit cost	0.63	0.57	0.65	0.70	0.70
RoA (normalized)	1.67	1.89	1.99	2.05	2.09
RoE (normalized)	12.18	13.06	12.90	13.14	14.20
Asset Quality					
GNPA	3.6	3.2	3.4	3.3	3.3
NNPA	2.7	2.2	2.7	2.7	2.7
Capital adequacy					
Tier 1 Ratio	19.4	19.9	22.3	20.0	19.1
CRAR	23.9	23.8	25.4	22.3	21.0
D/E (x)	6.2	6.1	5.4	5.8	6.2
Leverage (x)	7.3	7.2	6.4	6.8	7.2
RoA Tree (%)					
Interest income	9.5	10.2	10.6	10.6	10.7
Interest expense	5.6	5.6	5.8	5.8	5.9
Net interest income	4.2	4.9	5.1	5.1	5.1
Other income	0.0	0.0	0.0	0.0	0.0
Total income	4.2	4.9	5.1	5.1	5.1
Employee expense	1.1	1.3	1.3	1.3	1.2
Depreciation	0.1	0.1	0.1	0.1	0.1
Other expense	0.4	0.6	0.6	0.5	0.5
Opex	1.5	2.1	2.0	1.9	1.8
Profit before provisions	2.6	2.9	3.1	3.2	3.3
Provisions	0.6	0.5	0.6	0.7	0.7
Profit before tax	2.0	2.3	2.5	2.5	2.6
Tax expense	0.4	0.5	0.5	0.6	0.6
RoA	1.6	1.8	1.9	2.0	2.0

Source: Company, Emkay Research

Exhibit 18: Aditya Birla Sun Life AMC – Financial Summary

(Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Income Statement					
Fund management & advisory fee	12,635	12,266	11,775	12,749	13,823
Investment & other income	1,156	1,271	1,336	1,603	1,923
Total income	13,790	13,537	13,111	14,352	15,746
Total expense	5,138	5,598	4,851	5,310	5,826
Profit before tax	8,652	7,939	8,260	9,042	9,920
Tax expense	2,219	1,975	2,055	2,249	2,468
Profit after tax	6,433	5,964	6,205	6,792	7,452
Balance Sheet					
Shareholders' Equity	22,006	25,090	29,058	33,403	38,169
Total Assets	24,343	27,766	33,320	39,984	47,980
MF QAAUM	29,58,050	27,52,040	30,58,755	34,03,283	37,95,503
- o/w Equity AAUM	11,10,313	8,76,040	10,07,446	11,28,340	12,63,740
Total QAAUM	30,74,090	28,61,800	31,76,894	35,33,236	39,38,451
Key ratios (%)					
Profitability					
Fee yield	0.43	0.41	0.39	0.38	0.37
C/I ratio	37.3	41.4	37.0	37.0	37.0
PAT/QAAUM	0.22	0.20	0.21	0.20	0.20
RoE (normalized)	32.9	25.3	22.9	21.7	20.8

Source: Company, Emkay Research

Exhibit 19: Aditya Birla Sun Life Insurance – Financial Summary

Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Policyholders' account					
Gross written premium	1,21,402	1,50,697	1,70,662	2,03,177	2,41,952
Net earned premium	1,16,415	1,45,395	1,65,542	1,97,081	2,34,693
Investment income	53,020	34,576	61,732	72,686	85,760
Other income	1,291	3,409	3,882	4,621	5,503
Total revenue	1,70,725	1,83,380	2,31,156	2,74,389	3,25,956
Commission expense	5,962	8,436	9,605	11,435	13,617
Operating expenses	15,209	20,965	22,348	26,606	31,684
Benefits cost	1,47,115	1,49,317	1,93,771	2,30,078	2,73,190
Total expense	1,69,969	1,80,451	2,27,698	2,70,469	3,21,289
Surplus/Deficit	756	2,929	3,458	3,920	4,668
Shareholders' account					
Transfer from policyholders' account	756	2,929	3,458	3,920	4,668
Investment income	2,122	2,389	2,608	2,765	2,948
Expenses	1,468	3,780	4,158	4,573	5,031
Profit before tax	1,409	1,538	1,908	2,111	2,585
Tax expense	141	154	190	211	258
Profit after tax	1,268	1,385	1,718	1,900	2,327
Balance Sheet					
Sources of Funds					
Shareholders' Funds	25,486	29,261	30,979	32,880	35,206
Policyholders' Funds: Insurance reserves and provisions	5,91,187	6,77,645	7,96,875	9,39,297	11,09,164
Total	6,16,673	7,11,886	8,32,834	9,77,157	11,49,351
Application of Funds					
Shareholders' Investments	29,215	32,981	34,917	37,059	39,682
Policyholders' Investments	2,77,141	3,62,456	4,26,229	5,02,408	5,93,266
Assets Held to Cover Linked Liabilities	3,01,602	3,05,074	3,58,751	4,22,869	4,99,343
Other Asset	8,716	11,375	12,936	14,821	17,060
Total	6,16,673	7,11,886	8,32,834	9,77,157	11,49,351
Embedded Value Account					
Embedded Value	76,090	90,140	1,06,036	1,24,234	1,45,393
Annualised Premium Equivalent (APE)	24,600	34,783	35,412	40,965	47,399
New Business value	3,690	8,000	7,082	8,193	9,480
New Business Margin (%)	15.0	23.0	20.0	20.0	20.0
EV Operating Profit	9,950	17,200	15,896	18,198	21,159
Operating RoEV (%)	15.4	22.6	17.6	17.2	17.0
Key Ratio					
Return on Equity (%)	5.1	5.1	5.7	6.0	6.8
Commission expense/TWRP (%)	6.5	7.6	7.7	7.7	7.7
Operating expenses/TWRP (%)	16.5	18.9	17.9	18.0	18.0
Total expense (% of TWRP)	23.0	26.5	25.6	25.7	25.8
Total expense (% of Avg AUM)	3.73	4.49	4.20	4.27	4.33
Conservation ratio (%)	89.1	83.4	82.1	87.5	88.5

Source: Company, Emkay Research

Exhibit 20: Aditya Birla Health Insurance – Financial Summary

Policyholder Account (Y/E Mar, Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Gross Direct Premium (GDPI)	17,267	27,170	36,471	47,217	61,147
Gross Written Premium (GWP)	17,267	27,170	36,471	47,217	61,147
Net Written Premium (NWP)	13,481	21,212	32,277	42,495	55,032
Net Earned Premium (NEP)	11,893	18,378	26,745	37,386	48,764
Net incurred claims	8,273	11,886	18,186	25,049	32,184
Net commission expense	191	1,435	1,614	2,125	2,752
Operating expense	7,461	8,701	11,943	14,448	17,060
Total Expense	3,574	6,231	8,684	11,206	15,925
Underwriting result	(2054)	(2749)	(2830)	(2734)	(4032)
Investment income	707	1,101	2,328	3,161	4,228
Insurance result	-1,347	-1,647	-502	427	196
Operating profit	-3,325	873	-2,670	-1,075	996
Shareholder Account					
(Y/E Mar, Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Operating profit	-3,325	873	-2,670	-1,075	996
Investment income	235	435	782	990	1,050
Other income					
Expenses and provisions	25	3,497	30	30	30
Profit before tax	-3,114	-2,188	-1,919	-115	2,015
Tax expense	0	0	0	0	0
Profit after Tax	-3,114	-2,188	-1,919	-115	2,015
Balance Sheet					
(Y/E Mar, Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Source of Funds					
Shareholders fund	18,180	27,677	32,677	32,677	34,692
Fair value gains	0	4	5	5	5
Net worth including fair value gains	18,180	27,681	32,681	32,682	34,697
Borrowings					
Total	18,180	27,681	32,681	32,682	34,697
Application of Funds					
Investments					
Shareholders	3,446	7,995	14,050	13,947	15,761
Policyholders	11,794	21,548	29,073	40,055	52,782
Other Assets	1,170	1,435	1,478	1,508	1,538
Cash & Bank Balances	534	170	186	205	226
Other current assets	1,354	2,621	3,014	3,466	3,985
Net Current Assets	-11,188	-18,444	-28,985	-40,008	-52,563
Accumulated losses	12,959	15,147	17,065	17,180	17,180
Total	18,181	27,681	32,681	32,682	34,697
Key ratios					
(Y/E Mar, %)	FY22	FY23	FY24E	FY25E	FY26E
Retention ratio	78.1	78.1	88.5	90.0	90.0
Incurred claims ratio	69.6	64.7	68.0	67.0	66.0
Net commission ratio	1.4	6.8	5.0	5.0	5.0
Expense ratio	55.3	41.0	37.0	34.0	31.0
Combined ratio	126.3	112.5	110.0	106.0	102.0
GWP/Net worth	0.9	1.0	1.1	1.4	1.8
NWP/Net worth	0.7	0.8	1.0	1.3	1.6
Return on Equity	-19.5	-9.5	-6.4	-0.4	6.0

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
03-Aug-23	193	225	Buy	Avinash Singh
12-May-23	163	200	Buy	Avinash Singh
06-Mar-23	156	200	Buy	Avinash Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 5, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 5, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 5, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.